Galmed Pharmaceuticals earnings were -$8.7M for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. The latest GLMD earnings report on Jun 30, 2025 announced Q2 2025 earnings of -$2.5M, up 126% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, GLMD reported annual earnings of -$7.5M, with 8.8% growth. The next GLMD earnings date is Nov 10, 2025.
Galmed Pharmaceuticals Earnings Reports & History FAQ
What were Galmed Pharmaceuticals's earnings last quarter?
On GLMD's earnings call on Invalid Date, Galmed Pharmaceuticals (NASDAQ: GLMD) reported Q2 2025 earnings per share (EPS) of -$0.63, up 61.82% year over year. Total GLMD earnings for the quarter were -$2.50 million. In the same quarter last year, Galmed Pharmaceuticals's earnings per share (EPS) was -$1.65.
The next GLMD earnings call is Invalid Date. Add GLMD to your watchlist to be reminded of Galmed Pharmaceuticals's next earnings date.
Is Galmed Pharmaceuticals profitable or losing money?
As of the last Galmed Pharmaceuticals earnings report, Galmed Pharmaceuticals is currently losing money. Galmed Pharmaceuticals's net profit (also called net income) for the twelve months ending Jun 30, 2025 was -$8.72 million, a 48.26% increase year over year.
What was GLMD's earnings growth in the past year?
As of Galmed Pharmaceuticals's earnings date in Invalid Date, Galmed Pharmaceuticals's earnings has grown year over year. GLMD earnings in the past year totalled -$8.72 million.
What are Galmed Pharmaceuticals's earnings expectations?
The current EPS estimate for Galmed Pharmaceuticals's earnings report in Invalid Date is -$0.79.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.